{"id":"naloxone-nasal-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute opioid withdrawal symptoms (agitation, body aches, sweating)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone binds with high affinity to mu, delta, and kappa opioid receptors, displacing opioids and preventing their activation. When administered intranasally, it is rapidly absorbed through the nasal mucosa and quickly crosses the blood-brain barrier to reverse respiratory depression and other life-threatening effects of opioid overdose. The nasal spray formulation provides a non-invasive, needle-free route of administration suitable for emergency use by laypersons.","oneSentence":"Naloxone is a competitive opioid receptor antagonist that rapidly blocks opioid effects and reverses opioid overdose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:33.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal (emergency treatment)"},{"name":"Suspected or known opioid overdose with respiratory depression"}]},"trialDetails":[{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT04851301","phase":"PHASE1, PHASE2","title":"Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":259},{"nctId":"NCT04650841","phase":"EARLY_PHASE1","title":"The Role of the Opioid System in Placebo Effects on Pain and Social Rejection","status":"NOT_YET_RECRUITING","sponsor":"Trustees of Dartmouth College","startDate":"2026-09-01","conditions":"Pain, Rejection, Placebo Effect","enrollment":60},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT05776823","phase":"NA","title":"Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2023-05-05","conditions":"Opioid Use Disorder, Overdose","enrollment":267},{"nctId":"NCT06306391","phase":"PHASE1","title":"Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2024-03-05","conditions":"Healthy","enrollment":8},{"nctId":"NCT04828005","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-03-30","conditions":"Pharmacodynamic","enrollment":84},{"nctId":"NCT03897998","phase":"PHASE2","title":"Neural Correlates of Hypoalgesia Driven by Observation","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":182},{"nctId":"NCT06262347","phase":"NA","title":"Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2024-06-13","conditions":"Opioid Use Disorder, Pregnancy Related, Substance Use","enrollment":131},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":"Opioid Induced Respiratory Depression, Chronic Opioid Use","enrollment":24},{"nctId":"NCT06089707","phase":"PHASE3","title":"Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-09","conditions":"Opioid Use Disorder","enrollment":25},{"nctId":"NCT04764630","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-03-01","conditions":"Healthy Subjects, Opioid Antagonist, Pharmacokinetics","enrollment":21},{"nctId":"NCT05093296","phase":"PHASE2, PHASE3","title":"Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2021-12-02","conditions":"Alcohol Use Disorder, Alcoholism, Alcohol Addiction","enrollment":62},{"nctId":"NCT05377255","phase":"PHASE1","title":"Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2022-03-28","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT06064981","phase":"NA","title":"BE Intervention for Naloxone Uptake","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-01","conditions":"Harm Reduction","enrollment":137},{"nctId":"NCT04134767","phase":"NA","title":"Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)","status":"COMPLETED","sponsor":"April M Young","startDate":"2019-11-15","conditions":"Substance Use, HIV Infections, HCV Infection","enrollment":234},{"nctId":"NCT04303000","phase":"PHASE4","title":"Increasing Naloxone Access for Persons Who Use Opioids","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-07-11","conditions":"Naloxone","enrollment":111},{"nctId":"NCT03309449","phase":"NA","title":"A Usability Assessment of Naloxone by Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-08","conditions":"Drug Overdose","enrollment":138},{"nctId":"NCT03570099","phase":"","title":"Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2018-06-11","conditions":"Opioid Abuse","enrollment":2000},{"nctId":"NCT05218681","phase":"NA","title":"Nursing Attitudes Towards SUD","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-11-17","conditions":"Substance Use Disorders, Stigma, Social","enrollment":170},{"nctId":"NCT05363501","phase":"PHASE1","title":"Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"Pocket Naloxone Corp","startDate":"2021-01-21","conditions":"Opioid Overdose","enrollment":76},{"nctId":"NCT04713709","phase":"PHASE1","title":"A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder","status":"COMPLETED","sponsor":"Nasus Pharma","startDate":"2021-01-31","conditions":"Opioid Overdose","enrollment":46},{"nctId":"NCT05093309","phase":"NA","title":"Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone","status":"COMPLETED","sponsor":"Auburn University","startDate":"2018-09-18","conditions":"Opioid Overdose","enrollment":55},{"nctId":"NCT03518021","phase":"PHASE3","title":"Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-05-15","conditions":"Overdose, Drug Abuse","enrollment":286},{"nctId":"NCT02922959","phase":"NA","title":"A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2017-02-07","conditions":"Drug Overdose, Opioid-Related Disorders, Drug Addiction","enrollment":80},{"nctId":"NCT03223896","phase":"PHASE2","title":"Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2017-02-14","conditions":"Gambling, Opioid, Naloxone","enrollment":20},{"nctId":"NCT04025671","phase":"NA","title":"A Usability Assessment of Naloxone Administration by Untrained Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2017-08-23","conditions":"Harm Reduction, Opioid-use Disorder, Naloxone","enrollment":208},{"nctId":"NCT03430180","phase":"PHASE2","title":"Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder","status":"UNKNOWN","sponsor":"Finnish Institute for Health and Welfare","startDate":"2018-02-22","conditions":"Pathological Gambling, Gambling Disorder, Opioid Antagonist","enrollment":126},{"nctId":"NCT03827629","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2017-08-07","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT03827642","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2018-04-23","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT02307721","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-12","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT03386591","phase":"PHASE1","title":"Comparison of Naloxone Pharmacokinetics","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2018-01-03","conditions":"Opioid-use Disorder","enrollment":30},{"nctId":"NCT00716807","phase":"NA","title":"Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-01","conditions":"Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome","enrollment":46},{"nctId":"NCT01622504","phase":"PHASE1","title":"Naloxone Nasal Spray Pharmacokinetic Study","status":"UNKNOWN","sponsor":"Mitovie Pharma Ltd","startDate":"2012-06","conditions":"Opioid Overdose","enrollment":6},{"nctId":"NCT01567670","phase":"PHASE2, PHASE3","title":"Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray","status":"UNKNOWN","sponsor":"Lightlake Sinclair Ltd.","startDate":"2011-08","conditions":"Binge Eating Disorder","enrollment":138}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ARTHRALGIA"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"PNEUMONIA"},{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"CATHETER SITE HAEMORRHAGE"},{"count":1,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"CYANOSIS"}],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Naloxone Nasal Spray","genericName":"Naloxone Nasal Spray","companyName":"Pocket Naloxone Corp","companyId":"pocket-naloxone-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone is a competitive opioid receptor antagonist that rapidly blocks opioid effects and reverses opioid overdose. Used for Opioid overdose reversal (emergency treatment), Suspected or known opioid overdose with respiratory depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}